-transparent.png){kind=logo}
We report here a useful method for elimination of small cell lung cancer cells in vitro from bone marrow. A monoclonal antibody, TFS-2, which mediates complement lysis and recognizes an antigen present on small cell lung cancer cells but not lymphoid cells or bone marrow cells, was used to clear infiltrated bone marrow. The antibody in the presence of complement effectively killed tumor cells, but it was not cytotoxic to bone marrow cells. When mixed populations consisting of tumor cells and bone marrow cells were treated with antibody and complement, the tumor cells were also effectively killed, except when large numbers of bone marrow cells were present, whereas TFS-2 had no significant effect on bone marrow stem cells, as judged by colony-forming unit assays.
T Okabe, and
T Kaizu, and
K Ozawa, and
A Urabe, and
F Takaku
April 1985,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T Okabe, and
T Kaizu, and
K Ozawa, and
A Urabe, and
F Takaku
November 1990,
Cancer research,
T Okabe, and
T Kaizu, and
K Ozawa, and
A Urabe, and
F Takaku
January 1990,
Progress in clinical and biological research,
T Okabe, and
T Kaizu, and
K Ozawa, and
A Urabe, and
F Takaku
March 1983,
Cancer research,
T Okabe, and
T Kaizu, and
K Ozawa, and
A Urabe, and
F Takaku
February 1988,
European journal of cancer & clinical oncology,
T Okabe, and
T Kaizu, and
K Ozawa, and
A Urabe, and
F Takaku
August 1993,
Cancer research,
T Okabe, and
T Kaizu, and
K Ozawa, and
A Urabe, and
F Takaku
May 1985,
International journal of cancer,
T Okabe, and
T Kaizu, and
K Ozawa, and
A Urabe, and
F Takaku
February 1987,
Cancer research,
T Okabe, and
T Kaizu, and
K Ozawa, and
A Urabe, and
F Takaku
April 1996,
Biulleten' eksperimental'noi biologii i meditsiny,
T Okabe, and
T Kaizu, and
K Ozawa, and
A Urabe, and
F Takaku
November 1984,
Cancer research,
